Non-selective beta-blocker

This page covers all Non-selective beta-blocker drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Nuclear receptor subfamily 2 group E member 1, 5-hydroxytryptamine receptor 6, Cytochrome P450 1A2, Beta-1 and beta-2 adrenergic receptors.

Targets

Nuclear receptor subfamily 2 group E member 1, 5-hydroxytryptamine receptor 6, Cytochrome P450 1A2 · Beta-1 and beta-2 adrenergic receptors

Marketed (1)

• Inderal · Generic (originally ICI/AstraZeneca) · Neuroscience

Phase 3 pipeline (1)

• carvedilol immediate release · CTI-1, LLC · Cardiovascular
  Carvedilol immediate release is a beta-blocker that works by blocking the effects of the hormone epinephrine, also known as adrenaline, and by slowing the heart rate and reducing its workload.

Phase 2 pipeline (1)

• Carvedilol extended release only · GlaxoSmithKline · Cardiovascular
  Carvedilol extended release is a beta-blocker that works by blocking the effects of the hormone epinephrine, also known as adrenaline, and by slowing the heart rate and reducing its workload.